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Antrodia camphorata is used in folk medicine for the treatment of inﬂammation syndromes and liver-related diseases in Taiwan.
The goal of this study was to evaluate the eﬃcacy of the mycelial extract of A. camphorata (ACE) for the treatment of systemic
lupus erythematosus (SLE) in SLE-prone NZB/W F1 mice. After antibodies against double-stranded DNA appeared in NZB/W
mice, the mice were orally administered varying dosages of ACE (100, 200 and 400mgkg−1) for 5 consecutive days per week for
12 weeks via gavage. To assess the eﬃcacy of ACE, we measured SLE-associated biochemical and histopathological biomarkers
levels of blood urine nitrogen (BUN), blood creatinine, urine protein and urine creatinine and thickness of the kidney glomerular
basement membrane by staining with periodic acid-Schiﬀ. Antroquinonol, an active component of ACE, was investigated for anti-
inﬂammation activity in lipopolysaccharide-induced RAW 267.4 cells. ACE at 400mgkg−1 signiﬁcantly suppressed urine protein
and serum BUN levels and decreased the thickness of the kidney glomerular basement membrane. Antroquinonol signiﬁcantly
inhibited the production of tumor necrosis factor-α and interleukin-1β by 75 and 78%, respectively. In conclusion, ACE reduced
urine protein and creatinine levels and suppressed the thickening of the kidney glomerular basement membrane, suggesting that
ACE protects the kidney from immunological damage resulting from autoimmune disease.
1.Introduction
Systemic lupus erythematosus (SLE) is an autoimmune
disease for which the pathogenesis remains unclear [1].
Patients with SLE produce numerous antibodies against self-
antigens in several organs, such as skin, joints and kidneys
[2]. The clinical features include fever, photosensitivity,
serositis [3] and renal disease, the latter being the most
life threatening due to potential development of irreversible
kidney failure [4].
It has been suggested that in SLE hyperactive B cells
produce auto-antibodies against DNA fragments. These
antibodies can then attack the nuclear antigens of organs or
form immunocomplex precipitates that aﬀect microcircula-
tion, resulting in organ dysfunction [2]. When precipitated
immunocomplexes in the kidney result in glomerulitis,
patients will present with signiﬁcant amounts of protein
in the urine. Furthermore, the thickness of glomerular
basement membranes is increased in glomerulitis and results
in the reduction of blood creatinine clearance, which serves
asanimportantdiagnosticparameterforlupusnephritis[5].
The BXSB, MRL/lpr and NZB/W F1 mouse models
have been commonly used to validate drug regimens for
the treatment of SLE. Male BXSB mice characteristically
develop SLE faster than females, which is opposite of that
observed in humans [6]. MRL/lpr mice are characterized by
lymphadenosis, splenomegaly and polyarthritis. In NZB/W
F1 mice, females spontaneously produce auto-antibodies at
5-6 months of age and the mice die from kidney failure.
Among these mouse models, the symptoms of SLE-prone2 Evidence-Based Complementary and Alternative Medicine
Table 1: Analysis of SLE indicators among SLE-prone NZB/W F1 mice.
Treatment (dose) Body weight Anti-dsDNA IgG Urine protein Urine creatinine
(g) (a) (mgdL−1) (a) (mgdL−1) (a) (mgdL−1) (a)
Control-ddH2O (10mLkg−1) 35.4 ± 3.5 3.56 ± 2.79 89.2 ± 23.7 39.8 ± 12.5
Prednisolone (1.25mgkg−1) 34.4 ± 3.9 4.07 ± 4.14 88.2 ± 14.6 38.0 ± 7.0
ACE (100mgkg−1) 35.4 ± 3.6 4.86 ± 7.88 88.6 ± 16.7 33.7 ± 10.1
ACE (200mgkg−1) 36.8 ± 2.8 5.06 ± 7.87 83.3 ± 20.2 34.6 ± 9.5
ACE (400mgkg−1) 35.6 ± 4.6 5.29 ± 8.57 90.6 ± 19.8 40.6 ± 10.8
Normal (C57BL/6j mice) 18.2 ± 1.0 1.73 ± 0.53 75.1 ± 36.0 33.7 ± 15.7
(a)Data are expressed as mean ± SD.
NZB/W F1 mice are most similar to those of human SLE
patients [7, 8] and therefore provide the most promising
model for evaluation of anti-SLE drug activity.
Antrodia camphorata (Polyporaceae, Aphyllophorales), a
parasitic fungus on rotting trees of Cinnamomum kanehirai
Hay [9], is used in Taiwanese folk medicine for the treatment
of diarrhea, abdominal pain, hypertension, itching of the
skin and liver cancer. To date, A. camphorata has been
cultured as mycelium and has been shown to exhibit certain
anti-inﬂammation [10, 11], vasorelaxation [12]a n da n t i -
tumor cytotoxicity [13, 14] activities. However, the ability of
A. camphorata to inhibit auto-immune diseases has not been
subjected to scientiﬁc scrutiny.
To assess the anti-SLE eﬃcacy of A. camphorata mycelia,
we treated SLE-prone NZB/W F1 mice with extracts of a
camphorata mycelia and measured the diagnostic parameters
associated with lupus nephritis. Furthermore, RAW 264.7
cells, a mouse leukemic monocyte macrophage cell line,
were treated with the active ingredient of the extract,
antroquinonol, to evaluate its anti-inﬂammation activity.
2. Methods
2.1. Cells and Chemicals. RAW 264.7 cells (TIB-71) were
obtained from the American Type Culture Collection (Man-
assas, VA, USA). ACE and antroquinonol were provided
by Golden Biotechnology Co. (Taiwan). Prednisolone was
used as a positive control and was purchased from Chin
Teng Pharmacy Industrial Co. (Taiwan). Lipopolysaccharide
(LPS) was purchased from Sigma Co. (USA). All drugs were
stored at −20◦C and thawed at 37◦C before use.
2.2. Animals. Fifty NZB/W F1 female mice were purchased
from Jackson Laboratory (Bar Harbor, ME, USA) and
mice were maintained under climate-controlled conditions
and a 12 hours light-dark cycle. The animals were fed
standard rodent chow (PMI Nutrition International, USA).
Ten C57BL/6j female mice were purchased from the Animal
Center of the National Taiwan University and were used as
reference controls. All mice received human care and the
study protocol followed the guidelines of the Institutional
Animal Care and Use Committees of the Development
Center for Biotechnology (accredited by AAALAC).
2.3. Preparation of ACE. The A. camphorata used in this
study was authenticated by Dr Tzean Shang-Shong, Depart-
ment of Plant Pathology and Microbiology, National Taiwan
University, Taiwan. The mycelium of A. camphorata was
cultured in 1000mL growth medium containing 0.1gNaCl,
10g peptone, 2g yeast extract, 10g agar and 10g cereal
mixture (rice, wheat or corn), pH 7.5 at 25◦C for 12–14
weeks. After cultivation, 500g of lyophilized A. camphorata
mycelium was extracted with 2500mL n-hexane for 6 hours.
The n-hexane fraction, deﬁned as ACE (GD-66, product
nameandGD-AIDT7,batchname),wasconcentratedto20–
30mL via vacuum evaporation and the antroquinonol was
puriﬁed from ACE by silica gel chromatography (column
= 45cm, 5cm i.d.) (ASTM silica gel, Merck Co., Germany)
and eluted with n-hexane:ethyl acetate (10:3v/v). The
resulting eluate was further subjected to size exclusion
chromatography using Sephadex LH20 column (70cm long,
5cm i.d.) (AB gel, GE Healthcare Bio-Science, USA). The
antroquinonol (98% purity) was eluted with 95% ethanol as
described in the study of Lee et al. [9]; the ACE fraction was
determined to have 0.01% antroquinonol.
2.4. Drug Treatment. After NZB/W F1 mice were 23 weeks
old, blood was collected for determination of IgG against
double-stranded DNA (anti-dsDNA). Mice positive for anti-
dsDNA IgG were divided into ﬁve groups of 10 mice
each and treated with various concentrations of ACE or
prednisolone by gavage for 5 consecutive days per week
for 12 weeks as follows: (i) disease group, ddH2Ot r e a t -
ment (10mLkg−1), (ii) positive control group, prednisolone
treatment(1.25mgkg−1),(iii)ACEtreatment(100mgkg−1),
(iv) ACE treatment (200mgkg−1)a n d( v )A C Et r e a t m e n t
(400mgkg−1)( Table 1). Ten C57BL/6j mice were used as
reference group in this experiment.
2.5. Analysis of Blood Urea Nitrogen and Urine Protein. For
analysis of blood urea nitrogen (BUN), serum samples were
t h a w e da tr o o mt e m p e r a t u r ea n dt h e nl o a d e do naB U N
diagnostic kit slide. BUN was measured using an automated
analyzer(BUN Vitros DT6011, Johnson-Johnson, USA).For
analysis of urine protein, urine was collected by pressing
the bladder of mice with ﬁngertips every 2 weeks. Urine
protein was determined using the Bio-Rad Protein AssayEvidence-Based Complementary and Alternative Medicine 3
Table 2: Body weight change in NZB/W F1 mice with treatment time (a).
Treatment (dose) Week 0 (b),(c) Week 2 (b),(c) Week 4 (b),(c) Week 6 (b),(c) Week 8 (b),(c) Week 10 (b),(c) Week 12 (b),(c)
Control-ddH2O 35.4 ± 3.5
(0%)
36.4 ± 4.0
(2.8%)
37.4 ± 3.2
(5.6%)
38.3 ± 3.9
(8.2%)
38.9 ± 4.1
(9.9%)
37.6 ± 3.6
(6.2%)
35.8 ± 4.9
(1.1%) (10mLkg−1)
Prednisolone 34.4 ± 3.9
(0%)
34.0 ± 3.9
(−1.2%)
36.1 ± 4.0
(4.9%)
36.2 ± 4.2
(5.2%)
37.6 ± 3.5
(9.3%)
36.1 ± 3.3
(4.9%)
36.3 ± 3.4
(5.5%) (1.25mgkg−1)
ACE 35.4 ± 3.6
(0%)
35.2 ± 3.3
(−0.6%)
36.7 ± 3.2
(3.7%)
36.7 ± 4.2
(3.7%)
37.1 ± 5.7
(4.8%)
37.8 ± 1.8
(6.8%)
36.5 ± 3.1
(3.1%) (100mgkg−1)
ACE 36.8 ± 2.8
(0%)
37.4 ± 2.6
(1.6%)
37.5 ± 3.0
(1.9%)
38.3 ± 3.6
(4.1%)
38.7 ± 4.9
(5.2%)
38.9 ± 2.1
(5.7%)
39.0 ± 2.0
(6.0%) (200mgkg−1)
ACE 35.6 ± 4.6
(0%)
35.5 ± 4.5
(0%)
36.7 ± 4.5
(3.1%)
36.8 ± 5.0
(3.4%)
37.2 ± 6.1
(4.5%)
37.0 ± 8.2
(3.9%)
37.9 ± 6.3
(6.5%) (400mgkg−1)
(a)FiftyNZB/WF1femalemiceweredividedinto5groupsof10each.DiﬀerentdosesofACEandprednisolonewereadministratedbygavagesfor5consecutive
days per week for 12 weeks.
(b)Data are expressed as mean ± SD.
(c)Values in parentheses indicate percent increase in body weight compared to initial body weight.
Dye Reagent Concentrate according to the manufacturer’s
instructions, using bovine serum albumin as the standard.
Optical density (OD) was measured at 595nm.
2.6. Analysis of Serum and Urine Creatinine. Creatinine was
determinedbyaCreatinine(Direct)ReagentSet(EagleDiag-
nostics), according to the manufacturer’s instruction. The
urine samples were diluted with deionized water (1:10) and
mixed with an equal volume of the diluted reagent provided
in the kit in a 96-well microtiter plate and incubated for
15min at room temperature. The OD at 510nm was then
determined and the concentration of urine creatinine was
calculated as follows: creatinine (mgdL−1) = [(sample OD-
blank OD) × 6mgdL −1/(sample OD-blank OD)]. Serum
creatinine was measured using the urine creatinine protocol
but no dilution was needed for measuring serum creatinine.
2.7. Determination of Serum Anti-dsDNA IgG. The levels
of anti-dsDNA IgG were determined using a mouse anti-
dsDNA IgG ELISA kit (Alpha Diagnostic, USA), according
to the manufacturer’s instructions. In brief, blood serum
samples were diluted 100-fold with buﬀer (provided by the
kit) and added to a 96-well ELISA plate and incubated for 2
hoursatroomtemperature.Sampleswerethenwashedthrice
with washing buﬀer (provided by the kit) and horseradish
peroxidase–conjugated anti-IgG antibodies were then added
and incubated for 1 hour at room temperature. The samples
were washed ﬁve times with washing buﬀer and horseradish
peroxidase substrate solution was added and incubated for
15min at room temperature. The OD was measured at
450nm using an ELISA reader. (Multiskan EX, Thermo
Scientiﬁc Co., USA). The concentration of the anti-dsDNA
was calculated using a bovine serum albumin standard
calibration curve.
2.8. Histopathological Examination. After sacriﬁcing the ani-
mals, the kidneys were collected. A pathological examination
was performed and sections were paraﬃn ﬁxed and stained
by haematoxylin and eosin and periodic acid-Schiﬀ (PAS).
PAS was used to stain the kidney glomerular basement
membrane.
2.9. Anti-Inﬂammation Assay. RAW 264.7 cells were seeded
onto a 24-well plate at a density of 5 × 105 cells/well and
incubated at 37◦C for 24 hours under 5% CO2. RAW 264.7
cells were treated with varying concentrations of antro-
quinonol (MW 391) (0.256, 2.56, 25.6 and 256μM) for 24
hours in the presence of 1μgmL −1 LPS. After treatment, the
medium was analyzed by ELISA to determine the secretion
of tumor necrosis factor-α (TNF-α) and interleukin (IL)-1β
cytokines, as described in the study of Chang et al. [15].
2.10. Statistical Analysis. Statistical analysis of in vivo data
was performed using one-way ANOVA (SPSS software pack-
age). In vitro data were analyzed using the Student’s t-test.
Diﬀerences in values were considered signiﬁcant at P < .05.
3. Results
3.1. Decreased Serum BUN Levels in ACE-Treated NZB/W
Mice. Fifty NZB/W F1 female mice were divided into
5 groups of 10 mice each. Varying doses of ACE and
prednisolone were administrated by gavage 5 consecutive
days/week for 12 weeks. The body weight of NZB/W F1 mice
was recorded every 2 weeks (Table 2). The growth of NZB/W
F1 mice was not aﬀected in the ACE- and prednisolone-
treated groups, whereas the growth was signiﬁcantly inhib-
ited (only a 1.1% increase in body weight compared to initial
body weight) in vehicle-treated NZB/W F1 mice at the end
of the 12 week experiment. Mice displayed an increase in
body weight of 3.1, 6.0 and 6.5%, when treated with 100, 200
and 400mgkg−1 doses of ACE, respectively. The increase in
body weight reﬂected the improved condition of SLE mice,
suggesting that ACE might improve the cachexia symptoms
of SLE disease.4 Evidence-Based Complementary and Alternative Medicine
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Figure 1: ACE maintains kidney function in SLE-prone mice. The NZB/W F1 mice were treated with diﬀerent dosages of ACE (100, 200
and 400mgkg−1) and prednisolone (1.25mgkg−1) consecutively for 5 days per week for 12 weeks. At the end of experiment, blood of
experimental animals was collected and serum was determined for the concentration of (a) serum BUN and (b) serum creatinine. Before
the sacriﬁce of animals, urine was collected and then (c) urine protein and (d) urine creatinine were determined as described in Methods
section.
To evaluate whether kidney function in SLE-prone
NZB/W F1 mice was protected by ACE, serum creatinine
and BUN levels were analyzed following the 12 week ACE
treatmentregimen.AsshowninFigure 1(a),BUNlevelswere
elevated to 49.5 ± 1.0mgdL−1 in vehicle-treated NZB/W
F1 mice, whereas BUN levels were decreased to 14.2 ±
0.6mgdL−1 in prednisolone-treated mice. Likewise, BUN
levels were decreased among mice treated with diﬀerent
doses of ACE (23.0 ± 9.7mgdL−1 for 100mgkg−1 ACE
group, 17.8 ± 3.5mgdL−1 for 200mgkg−1 ACE group and
17.8 ± 3.3mgdL−1 for 400mgkg−1 ACE group). Thus, at
dosages of 200 and 400mgkg−1, ACE treatment decreased
BUN levels by 64%. Furthermore, lower creatinine levels
were observed in the prednisolone group (0.67mgdL−1)a n d
ACE groups (0.69mgdL−1 in 100mgkg−1 treatment group
and 0.62mgdL−1 in 400mgkg−1 treatment group) com-
pared to SLE-disease group (0.81mgdL−1)( Figure 1(b)).
Furthermore, prednisolone treatment decreased serum cre-
atinine levels to 0.67 ± 0.05mgdL−1 in NZB/W F1 mice as
did ACE treatment (serum creatinine = 0.69 ± 0.10mgdL−1
in the 100mgkg−1 ACE treatment group and 0.62 ±
0.07mgdL−1 in the 400mgkg−1 ACE treatment group)
compared to SLE-disease group of NZB/W F1 mice (serum
creatinine = 0.81 ± 0.14mgdL−1). These results suggested
that kidney function, including serum creatinine clearance,
is maintained by ACE treatment.
3.2. Attenuation of Nephritis in SLE-Prone NZB/W F1
Mice. To evaluate the severity of nephritis in ACE-treated
NZB/W F1 mice, urine protein and creatinine were ana-
lyzed, which are indicators of severity for lupus nephritis.
The concentration of urine protein in the SLE disease groupEvidence-Based Complementary and Alternative Medicine 5
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Figure 2: ACE inhibits immunological kidney damage in SLE-
prone mice. The NZB/W F1 mice were treated with diﬀerent
dosages of ACE (100, 200 and 400mgkg−1) and prednisolone
(1.25mgkg−1)c o n s e c u t i v e l yf o r5d a y sp e rw e e kf o r1 2w e e k s .A t
the end of experiment, blood of experimental animals was collected
and serum was tested for anti-dsDNA IgG using a mouse anti-ds
DNA IgG ELISA kit.
was dramatically increased to 581.8 ± 298.7mgdL−1 at the
end of the 12 week experiment, which was consistent with
the body weight loss and indicated the onset of nephritis
(Figure 1(c)). Prednisolone inhibited the increase in the
levels of urine protein by 82% and 100, 200 and 400mgkg−1
per dose of ACE inhibited urine protein by 69, 62 and
55%, respectively. As shown in Figure 1(d), the levels of
urine creatinine were normal in the SLE-disease group (40.9
± 0.6mgdL−1) but were increased in prednisolone-treated
mice (53.4 ± 5.1mgdL−1). In contrast, mice treated with
400mgkg−1 per dose of ACE had decreased urine creatinine
(34% lower) compared to the SLE-disease group. Compared
to creatinine in the blood, ACE maintained the glomerular
function of kidneys in clearance of creatinine.
3.3. ACE Modestly Decreases the Production of Serum Anti-
dsDNA Antibodies. In SLE, the levels of serum anti-dsDNA
increase with the progression of SLE. As shown in Figure 2,
the levels of anti-dsDNA IgG in vehicle-treated NZB/W F1
mice were dramatically elevated to 145.8 ± 46.4mgdL−1 at
the end of the 12 week period compared to the reference
normal C57BL/6j mice (1.72 ± 0.05mgdL−1), suggesting
that SLE was successfully established. Unexpectedly, the
levels of anti-dsDNA IgG were not inhibited by prednisolone
(144.5 ± 95.8mgdL−1) but the levels of anti-dsDNA IgG
were reduced to 79.6 ± 18.7mgdL−1 (45% inhibition) and
to 123.9 ± 27.6mgdL−1 (15% inhibition) in NZB/W F1
mice treated with 100 and 200mgkg−1 per dose of ACE,
respectively. Treatment of mice with 100mgkg−1 per dose of
ACE reduced the production of auto-antibodies, suggesting
that the suppression of the immune response might be one
of the pharmaceutical actions of ACE.
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Figure 3: ACE inhibits glomerular basement membrane thickening
in SLE-prone mice. The NZB/W F1 mice were treated with diﬀerent
dosages of ACE (100, 200 and 400mgkg−1) and prednisolone
(1.25mgkg−1)c o n s e c u t i v e l yf o r5d a y sp e rw e e kf o r1 2w e e k s .A t
the end of experiment, kidney was excised after sacriﬁce of animals
and subject to pathological examination. The thickness of kidney
glomerular basement membrane was determined by staining with
PAS. The thickness was measured using a microscope.
3.4. ACE Treatment Protects Kidneys via Inhibition of
Glomerular Basement Membrane Thickening. Because death
among SLE patients typically results from nephritis, we
examined the capillary walls of the kidney glomeruli by
staining with PAS. As shown in Figure 3, prednisolone
suppressed thickening of the glomeruli basement membrane
to 11 ± 1.32μm in SLE-prone mice, whereas the thickness
of the glomeruli basement membrane was 23 ± 2.98μm
in vehicle-treated mice. Thickening of the kidney glomeruli
basement membrane was also signiﬁcantly suppressed by
ACE treatment in a dose-dependent manner (thickness
= 19.1 ± 2.6μm, 17.5 ± 2.6μma n d1 7± 1.7μmf o r
mice treated with 100, 200 and 400mgkg−1 per dose of
ACE, respectively. Although ACE treatment only moderately
inhibited thickening of glomerular basement membrane,
it did protect the kidney glomeruli from immunological
damage. These results suggested that ACE treatment atten-
uated the onset of nephritis, thereby reducing the risk of
death.
3.5. Anti-Inﬂammation of Antroquinonol. To understand
the possible mechanism of ACE action, antroquinonol,
the major component of ACE, was investigated for anti-
inﬂammatory activity. RAW 264.7 cells were treated with
antroquinonol at 0.256, 2.56, 25.6 and 256μM. Antro-
quinonol inhibited the production of TNF-α and IL-1β in
LPS-induced inﬂammation in a dose-dependent manner
(Figures 4(a) and 4(b)). In particular, a dose of 256μM
antroquinonol inhibited LPS-induced TNF-α and IL-1β
secretion by 75 and 78%, respectively. This result showed
that antroquinonol might exert anti-inﬂammation activities
in ACE-treated SLE-prone mice.6 Evidence-Based Complementary and Alternative Medicine
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Figure 4: Antroquinonol inhibits cytokine secretion in LPS-treated
RAW 264.7 cells. The Raw 264.7 cells were treated with diﬀerent
concentrations of antroquinonol in the presence of LPS for 24
hours. The conditioned medium was subject to the determination
of (a) TNF-α and (b) IL-1β levels. Data point of experiment was
performed in triplicate and normalized by the induction of LPS as
percentage. ∗P < .05, ∗∗P < .01, ∗∗∗P < .001 versus LPS control,
signiﬁcant diﬀerence tested using student’s t-test.
4. Discussion
Nephritis in SLE patients is the major cause of death due
to auto-immune destruction of the kidneys. Elevated urine
protein and BUN are also observed among patients with
nephritis [16]. In this study, an extract of a camphorata,
a herbal medicine used in Taiwan, maintained normal
growth among SLE-prone mice and protected the kidneys
from immunological damage, allowing for normal kidney
function with respect to clearance of BUN and creati-
nine. Additionally, the thickening of the kidney glomerular
basement membrane was suppressed, suggesting that ACE
attenuated the progression of nephritis in SLE-prone mice.
Taken together, these results demonstrate that ACE protects
kidney function in SLE-prone animals via an unknown
mechanism, suggesting that ACE may have eﬃcacy for
treatment of SLE.
Pro-inﬂammatory cytokines play a central role in
acute and chronic liver inﬂammation. Among these pro-
inﬂammatorycytokines,TNF-αandIL-1βareinvolvedinthe
etiology of several diseases [17, 18]. Therefore, inhibition of
pro-inﬂammatory cytokines is a strategy for prevention of
immunological damage to organs [19]. Brennan et al. [20]
have also reported enhanced renal expression of TNF-α and
IL-1β in a SLE-prone murine model and that either TNF-α
or IL-1β accelerated renal injury. Thus, it has been suggested
that targeting the pro-inﬂammatory cytokines, such as TNF-
α and IL-1β, is a desirable strategy for treatment of human
SLE [21]. In this study, antroquinonol, the major active
component of ACE, inhibited the production of TNF-α and
IL-1β in LPS-induced RAW 264.7 cells, suggesting that this
anti-inﬂammatory activity may contribute to the function of
ACE in attenuation of the progression of lupus nephritis.
In conclusion, ACE reduced urine protein and creatinine
levels and caused a reduction in the kidney glomerular
basement membrane thickness, suggesting that ACE is able
to protect the kidneys from the immunological damage
characteristic of this autoimmune disease.
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